LATE BREAKING ABSTRACT: Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearr...

Date 27 September 2015
Event European Cancer Congress 2015
Session Early Drug Development II
Topics Clinical research
Basic Scientific Principles
Presenter Siena, S.